PULM · Pulmatrix, Inc.

Pulmatrix’s Q1 2026 results reflect a deliberate operational wind-down: R&D expenses fell to $3,000 — near zero — as all clinical development is on hold while the company pursues asset monetization or out-licensing. The $1.172 million net loss represents a 35% improvement year-over-year, primarily due to a $0.5 million reduction in G&A expenses, attributed to lower regulatory filing costs compared to Q1 2025 (which included S-4 preparation). Management explicitly tied this cost discipline to its strategic pivot, stating its Q1 focus was securing a 'strategic transaction for our company and our shareholders.' That objective culminated in the March 26, 2026 merger agreement with Eos SENOLYTIX — a gerotherapeutics company developing mitochondrial-targeting peptides — and a concurrent $1.0 million private placement of Series B Preferred Stock with an Eos affiliate. Crucially, the press release clarifies that common stockholders retain ~6% of the combined entity without dilution from the preferred issuance, preserving equity value ahead of the anticipated Q3 2026 closing. Cash declined modestly to $3.3 million as of March 31, 2026, but management states this balance is sufficient to fund operations through the merger close. The absence of forward guidance, revenue, or pipeline advancement updates underscores the transitional nature of this period: Pulmatrix is no longer operating as a standalone clinical-stage biopharma but as a vehicle executing a strategic combination, with its iSPERSE™ technology assets now positioned for potential licensing or royalty monetization (e.g., 2% royalties on Cipla’s non-U.S. PUR1900 sales). Investor attention must therefore shift entirely to merger execution risk, Eos’s valuation, and the terms governing the combined entity’s capital structure and governance.